Compare BKKT & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKKT | HELP |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | Canada |
| Employees | 559 | 50 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.3M | 281.4M |
| IPO Year | N/A | N/A |
| Metric | BKKT | HELP |
|---|---|---|
| Price | $9.29 | $5.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $13.00 | ★ $95.00 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.81 | $5.15 |
| 52 Week High | $49.79 | $8.55 |
| Indicator | BKKT | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 38.74 |
| Support Level | $8.90 | N/A |
| Resistance Level | $10.82 | $7.28 |
| Average True Range (ATR) | 0.78 | 0.65 |
| MACD | 0.06 | -0.21 |
| Stochastic Oscillator | 14.23 | 7.35 |
Bakkt Inc is focused on building the backbone of next-generation financial infrastructure. The company provides financial technology solutions that support institutional participation in digital assets. Its offerings include infrastructure related to bitcoin, tokenization, stablecoin payments, and AI-enabled financial services. The company specializes in providing solutions designed to meet institutional requirements for security, scale, and regulatory compliance.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.